Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LivaNova PLCLIVN · Entity 507 | President, Global Epilepsy | March 30, 2026 | April 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LivaNova PLC
Report date March 30, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,189 |
Ending reported balance
After 2026-03-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-30 · Exercise / conversion · Acquired 17,815 · Balance 30,566 F1: Reporting person had vested restricted stock units (RSUs) and vested performance stock units (PSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Row 2 · 2026-03-30 · Tax withholding · Disposed 8,377 · Balance 22,189 F2: Shares withheld to satisfy tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-30 · Exercise / conversion · Disposed 457 · Balance 0 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F4: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,329 |
Reported balance
After 2026-03-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-30 · Exercise / conversion · Disposed 1,330 · Balance 1,329 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F5: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,457 |
Reported balance
After 2026-03-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-30 · Exercise / conversion · Disposed 1,229 · Balance 2,457 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F6: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,684 |
Reported balance
After 2026-03-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-30 · Exercise / conversion · Disposed 2,343 · Balance 4,684 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F7: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,976 |
Reported balance
After 2026-03-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-03-30 · Grant · Acquired 8,976 · Balance 8,976 F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F12: On March 30, 2026, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2027. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-30 · Exercise / conversion · Disposed 3,243 · Balance 0 F8: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F9: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's cumulative free cash flow (FCF) for performance period 2023-2025 compared to a target determined by the 2022 Plan Administrator. The Company has determined that 122.0% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 122.0%, and the actual number of vested shares is presented as the quantity that was acquired. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-30 · Exercise / conversion · Disposed 3,156 · Balance 0 F8: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F10: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's Return on Investment Capital (ROIC) for performance period 2023-2025 compared to a target determined by the 2022 Plan Administrator. The Company has determined that 118.71% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 118.71%, and the actual number of vested shares is presented as the quantity that was acquired. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-30 · Exercise / conversion · Disposed 6,057 · Balance 0 F8: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F11: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2023 and ending December 31, 2025 relative to the total shareholder return of an index of companies, as determined by the 2022 Plan Administrator. The Company has determined that 113.89% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 113.89%, and the actual number of vested shares is presented as the quantity that was acquired. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,992 |
Reported balance
After 2026-03-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-30 · Grant · Acquired 2,992 · Balance 2,992 F8: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F13: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's revenue growth for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,992 |
Reported balance
After 2026-03-30 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-30 · Grant · Acquired 2,992 · Balance 2,992 F8: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F14: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2026 and ending December 31, 2028 relative to the total shareholder return of an index of companies, as determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,992 |
Reported balance
After 2026-03-30 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-30 · Grant · Acquired 2,992 · Balance 2,992 F8: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F15: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's adjusted earnings per share (EPS) for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting person had vested restricted stock units (RSUs) and vested performance stock units (PSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value.
F2: Shares withheld to satisfy tax liability.
F3: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement.
F4: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement.
F5: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement.
F6: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement.
F7: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement.
F8: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement.
F9: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's cumulative free cash flow (FCF) for performance period 2023-2025 compared to a target determined by the 2022 Plan Administrator. The Company has determined that 122.0% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 122.0%, and the actual number of vested shares is presented as the quantity that was acquired.
F10: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's Return on Investment Capital (ROIC) for performance period 2023-2025 compared to a target determined by the 2022 Plan Administrator. The Company has determined that 118.71% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 118.71%, and the actual number of vested shares is presented as the quantity that was acquired.
F11: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2023 and ending December 31, 2025 relative to the total shareholder return of an index of companies, as determined by the 2022 Plan Administrator. The Company has determined that 113.89% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 113.89%, and the actual number of vested shares is presented as the quantity that was acquired.
F12: On March 30, 2026, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2027. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement.
F13: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's revenue growth for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.
F14: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2026 and ending December 31, 2028 relative to the total shareholder return of an index of companies, as determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.
F15: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's adjusted earnings per share (EPS) for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 2,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 13 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,992 Underlying: Ordinary Shares · 2,992 shares Expires not disclosed F8 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F15 · derivative.exercise_date: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's adjusted earnings per share (EPS) for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F15 · derivative.expiration_date: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's adjusted earnings per share (EPS) for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 2,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 12 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,992 Underlying: Ordinary Shares · 2,992 shares Expires not disclosed F8 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F14 · derivative.exercise_date: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2026 and ending December 31, 2028 relative to the total shareholder return of an index of companies, as determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F14 · derivative.expiration_date: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2026 and ending December 31, 2028 relative to the total shareholder return of an index of companies, as determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 2,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 11 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,992 Underlying: Ordinary Shares · 2,992 shares Expires not disclosed F8 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F13 · derivative.exercise_date: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's revenue growth for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F13 · derivative.expiration_date: On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's revenue growth for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 8,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 10 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,976 Underlying: Ordinary Shares · 8,976 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F12 · derivative.exercise_date: On March 30, 2026, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2027. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. F12 · derivative.expiration_date: On March 30, 2026, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2027. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 6,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 9 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,057 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F11 · derivative.exercise_date: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2023 and ending December 31, 2025 relative to the total shareholder return of an index of companies, as determined by the 2022 Plan Administrator. The Company has determined that 113.89% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 113.89%, and the actual number of vested shares is presented as the quantity that was acquired. F11 · derivative.expiration_date: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2023 and ending December 31, 2025 relative to the total shareholder return of an index of companies, as determined by the 2022 Plan Administrator. The Company has determined that 113.89% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 113.89%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 3,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 8 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,156 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F10 · derivative.exercise_date: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's Return on Investment Capital (ROIC) for performance period 2023-2025 compared to a target determined by the 2022 Plan Administrator. The Company has determined that 118.71% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 118.71%, and the actual number of vested shares is presented as the quantity that was acquired. F10 · derivative.expiration_date: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's Return on Investment Capital (ROIC) for performance period 2023-2025 compared to a target determined by the 2022 Plan Administrator. The Company has determined that 118.71% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 118.71%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 3,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 7 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,243 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F9 · derivative.exercise_date: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's cumulative free cash flow (FCF) for performance period 2023-2025 compared to a target determined by the 2022 Plan Administrator. The Company has determined that 122.0% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 122.0%, and the actual number of vested shares is presented as the quantity that was acquired. F9 · derivative.expiration_date: On March 30, 2023, reporting person was granted PSUs to vest or lapse on March 30, 2026 based on the Company's cumulative free cash flow (FCF) for performance period 2023-2025 compared to a target determined by the 2022 Plan Administrator. The Company has determined that 122.0% of the underlying PSUs shall vest on March 30, 2026, subject to continued service during the vesting period and the award agreement. The performance achieved was 122.0%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 2,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 6 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,684 Underlying: Ordinary Shares · 2,343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F7 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement. F7 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 5 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,457 Underlying: Ordinary Shares · 1,229 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F6 · derivative.exercise_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F6 · derivative.expiration_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 4 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,329 Underlying: Ordinary Shares · 1,330 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F5 · derivative.exercise_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F5 · derivative.expiration_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · derivative · entry 3 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. F4 · derivative.exercise_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F4 · derivative.expiration_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 8,377 | $61.27 | $513,258.79 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · nonDerivative · entry 2 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,189 F2 · shares: Shares withheld to satisfy tax liability. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 17:20 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 17,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-26-000023 · wk-form4_1775078403.xml · nonDerivative · entry 1 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reporting person had vested restricted stock units (RSUs) and vested performance stock units (PSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | GrantStock Appreciation Rights · Derivative | 15,385 | $0.00 Strike: $39.13 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 14 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,385 Underlying: Ordinary Shares · 15,385 shares Expires 2035-03-30 F18 · derivative.exercise_date: On March 30, 2025, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 7,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 13 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,027 Underlying: Ordinary Shares · 7,027 shares Expires not disclosed F14 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F17 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's TSR for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F17 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on the Company's TSR for the three-year period beginning on January 1, 2025 and ending December 31, 2027 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 3,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 12 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,513 Underlying: Ordinary Shares · 3,513 shares Expires not disclosed F14 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F16 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's ROIC calculated for the performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F16 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's ROIC calculated for the performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 3,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 11 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,513 Underlying: Ordinary Shares · 3,513 shares Expires not disclosed F14 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F15 · derivative.exercise_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's FCF for performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F15 · derivative.expiration_date: On March 30, 2025, reporting person was granted PSUs to vest or lapse on March 30, 2028 based on how the Company's FCF for performance period 2025-2027 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 7,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 10 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,027 Underlying: Ordinary Shares · 7,027 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F13 · derivative.exercise_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F13 · derivative.expiration_date: On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 1,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 9 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2015 Plan and the award agreement. F12 · derivative.exercise_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2022 and ending December 31, 2024 relative to the total shareholder return of a peer group of companies, as determined by the 2015 Plan Administrator. The Company's performance achieved a result of 58%, and the actual number of vested shares is presented as the quantity that was acquired. F12 · derivative.expiration_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's total shareholder return (TSR) for the three-year period beginning on January 1, 2022 and ending December 31, 2024 relative to the total shareholder return of a peer group of companies, as determined by the 2015 Plan Administrator. The Company's performance achieved a result of 58%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 8 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2015 Plan and the award agreement. F11 · derivative.exercise_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's Return on Investment Capital (ROIC) for performance period 2022-2024 compared to a target determined by the 2015 Plan Administrator. The performance achieved was 78.5%, and the actual number of vested shares is presented as the quantity that was acquired. F11 · derivative.expiration_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's Return on Investment Capital (ROIC) for performance period 2022-2024 compared to a target determined by the 2015 Plan Administrator. The performance achieved was 78.5%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 805 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 7 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the 2015 Plan and the award agreement. F10 · derivative.exercise_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's cumulative adjusted free cash flow (FCF) for performance period 2022-2024 compared to a target determined by the 2015 Plan Administrator. The Company has determined that 88.1% of the underlying PSUs shall vest on March 30, 2025, subject to continued service during the vesting period and the award agreement. The performance achieved was 88.1%, and the actual number of vested shares is presented as the quantity that was acquired. F10 · derivative.expiration_date: On March 30, 2022, reporting person was granted PSUs to vest or lapse on March 30, 2025 based on the Company's cumulative adjusted free cash flow (FCF) for performance period 2022-2024 compared to a target determined by the 2015 Plan Administrator. The Company has determined that 88.1% of the underlying PSUs shall vest on March 30, 2025, subject to continued service during the vesting period and the award agreement. The performance achieved was 88.1%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,229 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 6 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,686 Underlying: Ordinary Shares · 1,229 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F8 · derivative.exercise_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F8 · derivative.expiration_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 5 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,659 Underlying: Ordinary Shares · 1,330 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F7 · derivative.exercise_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F7 · derivative.expiration_date: On March 30, 2023, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 4 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 457 Underlying: Ordinary Shares · 457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F5 · derivative.exercise_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. F5 · derivative.expiration_date: On March 30, 2022, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2023. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 426 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · derivative · entry 3 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 426 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F4 · derivative.exercise_date: On March 30, 2021, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2022. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. F4 · derivative.expiration_date: On March 30, 2021, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2022. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 2,835 | $39.13 | $110,933.55 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · nonDerivative · entry 2 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,751 F2 · shares: Shares withheld to satisfy tax liability. Read SEC document |
| March 30, 2025 Filed Apr 1, 2025 21:01 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 6,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-25-000029 · wk-form4_1743555682.xml · nonDerivative · entry 1 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) and vested performance stock units (PSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | GrantStock Appreciation Rights · Derivative | 10,746 | $0.00 Strike: $55.94 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 14 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,746 Underlying: Ordinary Shares · 10,746 shares Expires not disclosed F18 · derivative.exercise_date: On March 30, 2024, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2025. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F18 · derivative.expiration_date: On March 30, 2024, reporting person was granted stock appreciation rights (SARs) subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2025. The SARs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 4,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 13 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,915 Underlying: Ordinary Shares · 4,915 shares Expires not disclosed F14 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F17 · derivative.exercise_date: On March 30, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on the Company's TSR for the three-year period beginning on January 1, 2024 and ending December 31, 2026 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F17 · derivative.expiration_date: On March 30, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on the Company's TSR for the three-year period beginning on January 1, 2024 and ending December 31, 2026 relative to the TSR of an index of companies, as determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 2,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 12 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,457 Underlying: Ordinary Shares · 2,457 shares Expires not disclosed F14 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F16 · derivative.exercise_date: On March 30, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on how the Company's ROIC calculated for the performance period 2024-2026 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F16 · derivative.expiration_date: On March 30, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on how the Company's ROIC calculated for the performance period 2024-2026 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | GrantPerformance Stock Units · Derivative | 2,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 11 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,457 Underlying: Ordinary Shares · 2,457 shares Expires not disclosed F14 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the 2022 Plan and the award agreement. F15 · derivative.exercise_date: On March 30, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on how the Company's FCF for performance period 2024-2026 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. F15 · derivative.expiration_date: On March 30, 2024, reporting person was granted PSUs to vest or lapse on March 30, 2027 based on how the Company's FCF for performance period 2024-2026 compares to a target determined by the 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | GrantRestricted Stock Units · Derivative | 4,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 10 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,915 Underlying: Ordinary Shares · 4,915 shares Expires not disclosed F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share, in accordance with the terms of the LivaNova PLC 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F13 · derivative.exercise_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F13 · derivative.expiration_date: On March 30, 2024, reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting occurring on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 9 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each PSU represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the 2015 Plan and the terms of the award agreement. F12 · derivative.exercise_date: On March 30, 2021, the reporting person was granted 1,706 PSUs. The vesting of the PSUs depended on the Company's performance against a target of the total shareholder return (TSR) for fiscal years 2021, 2022, and 2023, compared to peer companies. The Company's performance achieved a result of 115%, and the actual number of vested shares is presented as the quantity that was acquired. F12 · derivative.expiration_date: On March 30, 2021, the reporting person was granted 1,706 PSUs. The vesting of the PSUs depended on the Company's performance against a target of the total shareholder return (TSR) for fiscal years 2021, 2022, and 2023, compared to peer companies. The Company's performance achieved a result of 115%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 1,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 8 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each PSU represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the 2015 Plan and the terms of the award agreement. F11 · derivative.exercise_date: On March 30, 2021, the reporting person received a grant of 853 PSUs. The number of PSUs that vested was the result of the Company's Return on Investment Capital (ROIC) for fiscal year 2021 with additional two years service condition. The performance achieved was 151.30%, and the actual number of vested shares is presented as the quantity that was acquired. F11 · derivative.expiration_date: On March 30, 2021, the reporting person received a grant of 853 PSUs. The number of PSUs that vested was the result of the Company's Return on Investment Capital (ROIC) for fiscal year 2021 with additional two years service condition. The performance achieved was 151.30%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionPerformance Stock Units · Derivative | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 7 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,706 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each PSU represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the 2015 Plan and the terms of the award agreement. F10 · derivative.exercise_date: On March 30, 2021, the reporting person received a grant of 853 PSUs. The number of PSUs that vested was the result of the Company's performance against a target related to Free Cash Flow (FCF) for fiscal year 2021 with additional two years service condition. The performance achieved was 200%, and the actual number of vested shares is presented as the quantity that was acquired. F10 · derivative.expiration_date: On March 30, 2021, the reporting person received a grant of 853 PSUs. The number of PSUs that vested was the result of the Company's performance against a target related to Free Cash Flow (FCF) for fiscal year 2021 with additional two years service condition. The performance achieved was 200%, and the actual number of vested shares is presented as the quantity that was acquired. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 1,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 6 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,989 Underlying: Ordinary Shares · 1,330 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share, in accordance with the terms of the LivaNova PLC 2022 Incentive Award Plan (the 2022 Plan) and the award agreement. F8 · derivative.exercise_date: The reporting person was granted 5,319 RSUs on March 30, 2023, subject to a four-year vesting in equal annual installments, which began on March 30, 2024. The unvested RSUs reported here vest 25% on March 30, 2025, March 30, 2026, and March 30, 2027. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. F8 · derivative.expiration_date: The reporting person was granted 5,319 RSUs on March 30, 2023, subject to a four-year vesting in equal annual installments, which began on March 30, 2024. The unvested RSUs reported here vest 25% on March 30, 2025, March 30, 2026, and March 30, 2027. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2022 Plan and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 5 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914 Underlying: Ordinary Shares · 457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F6 · derivative.exercise_date: The reporting person was granted 1,828 RSUs on March 30, 2022, subject to a four-year vesting in equal annual installments, which began on March 30, 2023. The remaining unvested RSUs reported here vest 25% on March 30, 2025 and March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. F6 · derivative.expiration_date: The reporting person was granted 1,828 RSUs on March 30, 2022, subject to a four-year vesting in equal annual installments, which began on March 30, 2023. The remaining unvested RSUs reported here vest 25% on March 30, 2025 and March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 427 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 4 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426 Underlying: Ordinary Shares · 427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F5 · derivative.exercise_date: The reporting person was granted 1,706 RSUs on March 30, 2021, subject to a four-year vesting in equal annual installments, which began on March 30, 2022. The remaining unvested RSUs reported here vest 25% on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. F5 · derivative.expiration_date: The reporting person was granted 1,706 RSUs on March 30, 2021, subject to a four-year vesting in equal annual installments, which began on March 30, 2022. The remaining unvested RSUs reported here vest 25% on March 30, 2025. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionRestricted Stock Units · Derivative | 573 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · derivative · entry 3 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one Ordinary Share of the Company in accordance with the terms of the LivaNova PLC 2015 Incentive Award Plan (the 2015 Plan) and the award agreement. F4 · derivative.exercise_date: The reporting person was granted 2,295 RSUs on March 30, 2020, subject to a four-year vesting in equal annual installments, which began on March 30, 2021. RSUs reported here vested 25% on March 30, 2024. The RSUs were subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. F4 · derivative.expiration_date: The reporting person was granted 2,295 RSUs on March 30, 2020, subject to a four-year vesting in equal annual installments, which began on March 30, 2021. RSUs reported here vested 25% on March 30, 2024. The RSUs were subject to forfeiture prior to vesting in accordance with the terms of the 2015 Plan and the award agreement. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Tax withholdingOrdinary Shares | 3,643 | $55.94 | $203,789.42 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · nonDerivative · entry 2 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,562 F2 · shares: The referenced shares were withheld from distribution to satisfy tax liability. Read SEC document |
| March 30, 2024 Filed Apr 2, 2024 21:22 UTC | LivaNova PLC LIVN · Entity 507 | Exercise / conversionOrdinary Shares | 7,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001639691-24-000049 · wk-form4_1712107347.xml · nonDerivative · entry 1 Bolton Stephanie · CIK 0002012558 · President, Global Epilepsy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Reporting person had vested restricted stock units (RSUs) and performance stock units (PSUs) settled in Ordinary Shares of LivaNova PLC (the Company). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.